Replies to post #28058 on Marker Therapeutics Inc (MRKR)

[poods]

I think the low cost of manufacture is well known. I think the revenue potential comes from this being used in both metastatic disease and as an adjuvant. A lot of patients fall into those categories. Take melanoma. Currently adjuvant therapy for stage 3 disease is anti-PD1, which has serious side effects (IRAE). Many of the anti9gens MRKR uses in pep mixes are expressed on melanoma. If Multi-TAA is better than anti-PD1 in an adjuvant setting for stage 3 disease or it can be used for earlier stage disease because of absence of toxicity, there is a large patient number that might be treatment candidates. Same case in other high, or even moderate risk patients rendered NED by surgery.